Logo image of HYL.BR

HYLORIS PHARMACEUTICALS SA (HYL.BR) Stock Fundamental Analysis

EBR:HYL - Euronext Brussels - BE0974363955 - Common Stock - Currency: EUR

6.88  -0.02 (-0.29%)

Fundamental Rating

4

Overall HYL gets a fundamental rating of 4 out of 10. We evaluated HYL against 53 industry peers in the Pharmaceuticals industry. HYL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. HYL shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year HYL has reported negative net income.
In the past year HYL has reported a negative cash flow from operations.
In the past 5 years HYL always reported negative net income.
In the past 5 years HYL always reported negative operating cash flow.
HYL.BR Yearly Net Income VS EBIT VS OCF VS FCFHYL.BR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

HYL has a worse Return On Assets (-15.34%) than 79.25% of its industry peers.
The Return On Equity of HYL (-19.73%) is worse than 75.47% of its industry peers.
Industry RankSector Rank
ROA -15.34%
ROE -19.73%
ROIC N/A
ROA(3y)-22.4%
ROA(5y)-19.16%
ROE(3y)-27.06%
ROE(5y)-23.47%
ROIC(3y)N/A
ROIC(5y)N/A
HYL.BR Yearly ROA, ROE, ROICHYL.BR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 200

1.3 Margins

HYL's Gross Margin of 97.32% is amongst the best of the industry. HYL outperforms 96.23% of its industry peers.
HYL's Gross Margin has improved in the last couple of years.
HYL does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 97.32%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.27%
GM growth 5Y28.78%
HYL.BR Yearly Profit, Operating, Gross MarginsHYL.BR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

More info and screens

6

2. Health

2.1 Basic Checks

HYL does not have a ROIC to compare to the WACC, probably because it is not profitable.
HYL has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, HYL has more shares outstanding
Compared to 1 year ago, HYL has a worse debt to assets ratio.
HYL.BR Yearly Shares OutstandingHYL.BR Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
HYL.BR Yearly Total Debt VS Total AssetsHYL.BR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

HYL has an Altman-Z score of 10.07. This indicates that HYL is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of HYL (10.07) is better than 96.23% of its industry peers.
A Debt/Equity ratio of 0.06 indicates that HYL is not too dependend on debt financing.
HYL has a better Debt to Equity ratio (0.06) than 84.91% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Altman-Z 10.07
ROIC/WACCN/A
WACC7.69%
HYL.BR Yearly LT Debt VS Equity VS FCFHYL.BR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M

2.3 Liquidity

A Current Ratio of 4.15 indicates that HYL has no problem at all paying its short term obligations.
HYL has a Current ratio of 4.15. This is amongst the best in the industry. HYL outperforms 98.11% of its industry peers.
A Quick Ratio of 4.15 indicates that HYL has no problem at all paying its short term obligations.
The Quick ratio of HYL (4.15) is better than 100.00% of its industry peers.
Industry RankSector Rank
Current Ratio 4.15
Quick Ratio 4.15
HYL.BR Yearly Current Assets VS Current LiabilitesHYL.BR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

7

3. Growth

3.1 Past

HYL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 55.62%, which is quite impressive.
The Revenue has grown by 448.86% in the past year. This is a very strong growth!
The Revenue has been growing by 147.54% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)55.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.41%
Revenue 1Y (TTM)448.86%
Revenue growth 3Y39.79%
Revenue growth 5Y147.54%
Sales Q2Q%364.4%

3.2 Future

Based on estimates for the next years, HYL will show a very strong growth in Earnings Per Share. The EPS will grow by 69.34% on average per year.
Based on estimates for the next years, HYL will show a very strong growth in Revenue. The Revenue will grow by 125.35% on average per year.
EPS Next Y25.75%
EPS Next 2Y2.37%
EPS Next 3Y69.34%
EPS Next 5YN/A
Revenue Next Year88.77%
Revenue Next 2Y88.57%
Revenue Next 3Y125.35%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
HYL.BR Yearly Revenue VS EstimatesHYL.BR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M 80M 100M
HYL.BR Yearly EPS VS EstimatesHYL.BR Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 0 1 -1

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

HYL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year HYL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HYL.BR Price Earnings VS Forward Price EarningsHYL.BR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HYL.BR Per share dataHYL.BR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1

4.3 Compensation for Growth

HYL's earnings are expected to grow with 69.34% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.37%
EPS Next 3Y69.34%

More info and screens

0

5. Dividend

5.1 Amount

HYL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HYLORIS PHARMACEUTICALS SA

EBR:HYL (7/30/2025, 7:00:00 PM)

6.88

-0.02 (-0.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A N/A
Earnings (Next)09-26 2025-09-26
Inst Owners0.02%
Inst Owner ChangeN/A
Ins Owners56.62%
Ins Owner ChangeN/A
Market Cap192.64M
Analysts80
Price Target14.28 (107.56%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.44%
PT rev (3m)2.44%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-24.89%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 22.78
P/FCF N/A
P/OCF N/A
P/B 5.99
P/tB 6.81
EV/EBITDA N/A
EPS(TTM)-0.23
EYN/A
EPS(NY)-0.42
Fwd EYN/A
FCF(TTM)-0.26
FCFYN/A
OCF(TTM)-0.25
OCFYN/A
SpS0.3
BVpS1.15
TBVpS1.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -15.34%
ROE -19.73%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 97.32%
FCFM N/A
ROA(3y)-22.4%
ROA(5y)-19.16%
ROE(3y)-27.06%
ROE(5y)-23.47%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.27%
GM growth 5Y28.78%
F-Score3
Asset Turnover0.2
Health
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 45.83%
Cap/Sales 3.51%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.15
Quick Ratio 4.15
Altman-Z 10.07
F-Score3
WACC7.69%
ROIC/WACCN/A
Cap/Depr(3y)212.59%
Cap/Depr(5y)303.89%
Cap/Sales(3y)40.52%
Cap/Sales(5y)102.37%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)55.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.41%
EPS Next Y25.75%
EPS Next 2Y2.37%
EPS Next 3Y69.34%
EPS Next 5YN/A
Revenue 1Y (TTM)448.86%
Revenue growth 3Y39.79%
Revenue growth 5Y147.54%
Sales Q2Q%364.4%
Revenue Next Year88.77%
Revenue Next 2Y88.57%
Revenue Next 3Y125.35%
Revenue Next 5YN/A
EBIT growth 1Y59.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-0.56%
EBIT Next 3Y91.83%
EBIT Next 5YN/A
FCF growth 1Y46.9%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y46.11%
OCF growth 3YN/A
OCF growth 5YN/A